3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
10
Head & Neck
6
Other hematologic neoplasm
2
Thoracic
1
Sarcoma
1
Myeloid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Classical hematology
1
Conditions
Prostatic Neoplasms
1641
Carcinoma, Renal Cell
504
Urinary Bladder Neoplasms
462
Carcinoma, Transitional Cell
234
Breast Neoplasms
228
Kidney Neoplasms
217
Neoplasms
194
Carcinoma, Non-Small-Cell Lung
173
Colorectal Neoplasms
172
Ovarian Neoplasms
163
Melanoma
162
Neoplasm Metastasis
143
Lung Neoplasms
128
Non-Muscle Invasive Bladder Neoplasms
107
Pancreatic Neoplasms
103
Stomach Neoplasms
101
Uterine Cervical Neoplasms
93
Squamous Cell Carcinoma of Head and Neck
86
Endometrial Neoplasms
84
Carcinoma, Hepatocellular
77
Sarcoma
75
Esophageal Neoplasms
72
Head and Neck Neoplasms
70
Triple Negative Breast Neoplasms
67
Adenocarcinoma
66
Colonic Neoplasms
53
Testicular Neoplasms
52
Disease
47
Urologic Neoplasms
46
Wilms Tumor
45
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Epstein-Barr Virus Infections
×
Genitourinary
×
1 year
×
Clear all
NCT05592626
2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
365 enrolled